Cover Image
市場調查報告書

便秘性大腸激躁症 (IBS-C) 治療藥的全球市場的未來預測

GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025

出版商 Inkwood Research 商品編碼 535785
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
便秘性大腸激躁症 (IBS-C) 治療藥的全球市場的未來預測 GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025
出版日期: 2017年08月01日 內容資訊: 英文 122 Pages
簡介

本報告提供全球便秘性大腸激躁症 (IBS-C) 治療藥的市場未來展望相關分析,疾病概要和市場基本結構,主要的市場推動及阻礙要素,市場整體及各類型、各處方手段、各地區的市場趨勢預測 (總計10年份),目前市場向心力的水準企業間競爭趨勢,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場概要

  • 市場定義
  • 市場概要
  • 有前途的投資方案
  • 主要的治療藥製造商在市場上的定位
  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 課題

第5章 全球IBS-C治療藥市場:藥物的各類型 (以金額為準,今後9年份)

  • 概要
    • LUBIPROSTONE
    • LINACLOTIDE
    • 興奮性瀉藥
    • 滲透性瀉藥
    • 其他 PSYLLIUM):質性資訊
  • 開發平台上的治療藥分析:PLECANATIDE

第6章 全球IBS-C治療藥市場:各處方手段 (以金額為準,今後9年份)

  • 處方藥
    • 品牌藥
    • 學名藥
  • 成藥

第7章 主要指標

  • 波特的五力分析
  • 供應商環境
  • 市場機會矩陣

第8章 全球IBS-C治療藥市場:各地區 (以金額為準,今後9年份)

  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國等)
  • 亞太地區 (中國,日本等)
  • 其他的國家 (RoW:中東、非洲,南美等)

第9章 企業簡介

  • CATALENT PHARMACEUTICALS SOLUTIONS
    • 概要
    • 產品系列
    • SCOT分析
    • 策略發展情形
  • NESTLE
  • ABBOTT LABORATORIES
  • SYNERGY PHARMACEUTICALS
  • SUCAMPO PHARMACEUTICALS
  • NOVARTIS PHARMA AG
  • Astellas Pharma Inc.
  • ARDELYX, INC.
  • SYNTHETIC BIOLOGICS, INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • BAMA-GEVE, SLU
  • FERRING BV
  • IRONWOOD PHARMACEUTICALS, INC.
  • SALIX PHARMACEUTICALS LTD
  • NORGINE B.V.
  • PROMETHEUS LABORATORIES INC.
  • ACTAVIS NORDIC A/S
  • ALBIREO PHARMA INC
  • YUHAN CORP
  • ASTRAZENECA PLC
  • THE MENARINI GROUP
  • 小野藥品工業

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 6718

KEY FINDINGS

The global IBS-C drug market is expected to grow at a CAGR of 6.30% during the forecast period of 2017 - 2025. Some of the primary factors responsible for the growth in the market are the ease of availability of effective drugs in the market, modern dietary habits affecting the health, various psychological factors affecting the irritable bowel syndrome and the opportunity of improved and efficient drugs in the pipeline with many first-in-class molecules

MARKET INSIGHTS

The global IBS-C drug market is segmented on the type of drug and prescription. The Drugs type is further classified into Linaclotide, Lubiprostone, Osmotic Laxatives, Stimulant Laxatives, and others. Of these, lubiprostone is a highly popular drug in the market. The market by Prescription type is further segmented into prescribed drugs and over the counter drugs. The over the counter drugs are leading this segment since no prescription from a doctor is required.

REGIONAL INSIGHTS

The global IBS-C drug market is geographically divided into North America (U.S. & Canada), Europe (Germany, UK, and RoE), Asia Pacific (Japan, China, and RoAPAC) and Rest of the World (Latin America and MENA). Of these, the North America region is anticipated to dominate the global IBS-C drug market over the forecast period on account of its highly developed healthcare systems and advanced medical devices industry.

COMPETITIVE INSIGHTS

Some of the major players in the global IBS-C drug market include Nestle, Catalent Pharma Solutions, Abbot Laboratories, Sucampo Pharmaceuticals, Synergy Pharmaceuticals, Novartis, etc.

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY

4. MARKET OVERVIEW

  • 4.1. MARKET DEFINITION
  • 4.2. KEY MARKET INSIGHTS
  • 4.3. ATTRACTIVE INVESTMENT SCENARIO
  • 4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
  • 4.5. DRIVERS
    • 4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
    • 4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
    • 4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
    • 4.5.4. IBS CAN BE A HERITABILITY ISSUE
    • 4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
  • 4.6. RESTRAINTS
    • 4.6.1. STRICT FDA REGULATIONS
    • 4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
  • 4.7. OPPORTUNITIES
    • 4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
    • 4.7.2. HIGH UNMET NEEDS
  • 4.8. CHALLENGES
    • 4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS

5. GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)

  • 5.1. OVERVIEW
    • 5.1.1. LUBIPROSTONE
    • 5.1.2. LINACLOTIDE
    • 5.1.3. STIMULANT LAXATIVES
    • 5.1.4. OSMOTIC LAXATIVES
    • 5.1.5. OTHERS (PSYLLIUM) - QUALITATIVE INFORMATION
  • 5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)

6. GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

  • 6.1. PRESCRIBED DRUGS
    • 6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
    • 6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  • 6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

  • 7.1. PORTERS FIVE FORCE ANALYSIS
    • 7.1.1. INTENSITY OF COMPETITIVE RIVALRY
    • 7.1.2. BARGAINING POWER OF SUPPLIERS
    • 7.1.3. BARGAINING POWER OF BUYERS
    • 7.1.4. THREAT OF SUBSTITUTE PRODUCTS
    • 7.1.5. THREAT OF NEW ENTRANTS
  • 7.2. VENDOR LANDSCAPE
  • 7.3. OPPORTUNITY MATRIX

8. GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

  • 8.1. NORTH AMERICA
    • 8.1.1. US
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UK
    • 8.2.2. GERMANY
    • 8.2.3. REST OF THE EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. REST OF ASIA PACIFIC
  • 8.4. REST OF THE WORLD
    • 8.4.1. MIDDLE EAST AND AFRICA
    • 8.4.2. LATIN AMERICA
    • 8.4.3. REST OF THE ROW

9. COMPANY PROFILES

  • 9.1. CATALENT PHARMACEUTICALS SOLUTIONS
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. SCOT ANALYSIS
    • 9.1.4. STRATEGIC MOVES
  • 9.2. NESTLE
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCTS PORTFOLIO
    • 9.2.3. SCOT ANALYSIS
    • 9.2.4. STRATEGIC MOVES
  • 9.3. ABBOTT LABORATORIES
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SCOT ANALYSIS
    • 9.3.4. STRATEGIC MOVES
  • 9.4. SYNERGY PHARMACEUTICALS
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCTS PORTFOLIO
    • 9.4.3. SCOT ANALYSIS
    • 9.4.4. STRATEGIC MOVES
  • 9.5. SUCAMPO PHARMACEUTICALS
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SCOT ANALYSIS
    • 9.5.4. STRATEGIC MOVES
  • 9.6. NOVARTIS PHARMA AG
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCTS PORTFOLIO
    • 9.6.3. SCOT ANALYSIS
    • 9.6.4. STRATEGIC MOVES
  • 9.7. ASTELLAS PHARMACEUTICALS
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SCOT ANALYSIS
    • 9.7.4. STRATEGIC MOVES
  • 9.8. ARDELYX, INC.
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SCOT ANALYSIS
    • 9.8.4. STRATEGIC MOVES
  • 9.9. SYNTHETIC BIOLOGICS, INC.
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
    • 9.9.4. STRATEGIC MOVES
  • 9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SCOT ANALYSIS
    • 9.10.4. STRATEGIC MOVES
  • 9.11. BAMA-GEVE, SLU
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SCOT ANALYSIS
  • 9.12. FERRING BV
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SCOT ANALYSIS
    • 9.12.4. STRATEGIC MOVES
  • 9.13. IRONWOOD PHARMACEUTICALS, INC.
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SCOT ANALYSIS
    • 9.13.4. STRATEGIC MOVES
  • 9.14. SALIX PHARMACEUTICALS LTD
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SCOT ANALYSIS
    • 9.14.4. STRATEGIC MOVES
  • 9.15. NORGINE B.V.
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. SCOT ANALYSIS
    • 9.15.4. STRATEGIC MOVES
  • 9.16. PROMETHEUS LABORATORIES INC.
    • 9.16.1. OVERVIEW
    • 9.16.2. PRODUCT PORTFOLIO
    • 9.16.3. SCOT ANALYSIS
    • 9.16.4. STRATEGIC MOVES
  • 9.17. ACTAVIS NORDIC A/S
    • 9.17.1. OVERVIEW
    • 9.17.2. PRODUCT PORTFOLIO
    • 9.17.3. SCOT ANALYSIS
    • 9.17.4. STRATEGIC MOVES
  • 9.18. ALBIREO PHARMA INC
    • 9.18.1. OVERVIEW
    • 9.18.2. PRODUCT PORTFOLIO
    • 9.18.3. SCOT ANALYSIS
    • 9.18.4. STRATEGIC MOVES
  • 9.19. YUHAN CORP
    • 9.19.1. OVERVIEW
    • 9.19.2. PRODUCT PORTFOLIO
    • 9.19.3. SCOT ANALYSIS
    • 9.19.4. STRATEGIC MOVES
  • 9.20. ASTRAZENECA PLC
    • 9.20.1. OVERVIEW
    • 9.20.2. PRODUCT PORTFOLIO
    • 9.20.3. SCOT ANALYSIS
    • 9.20.4. STRATEGIC MOVES
  • 9.21. THE MENARINI GROUP
    • 9.21.1. OVERVIEW
    • 9.21.2. PRODUCT PORTFOLIO
    • 9.21.3. SCOT ANALYSIS
    • 9.21.4. STRATEGIC MOVES
  • 9.22. ONO PHARMACEUTICAL CO., LTD.
    • 9.22.1. OVERVIEW
    • 9.22.2. PRODUCT PORTFOLIO
    • 9.22.3. SCOT ANALYSIS
    • 9.22.4. STRATEGIC MOVES

LIST OF TABLES

  • TABLE 1 GLOBAL IBS-C MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
  • TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
  • TABLE 4 POPULATION OF ASIA BY AGE GROUP IN VARIOUS SUB REGION, JULY 2013
  • TABLE 5 GLOBAL IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
  • TABLE 6 GLOBAL LUBIPROSTONE MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 7 PRODUCT PROFILE (LUBIPROSTONE)
  • TABLE 8 GLOBAL LINACLOTIDE MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 9 PRODUCT PROFILE (LINACLOTIDE)
  • TABLE 10 GLOBAL STIMULANT LAXATIVES MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 11 GLOBAL BISACODYL MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 12 PRODUCT PROFILE (BISACODYL)
  • TABLE 13 GLOBAL SENNA MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 14 PRODUCT PROFILE (SENNA)
  • TABLE 15 GLOBAL LACTULOSE MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 16 PRODUCT PROFILE (LACTULOSE)
  • TABLE 17 GLOBAL POLYETHYLENE GLYCOL MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 18 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
  • TABLE 19 PRODUCT PROFILE (PSYLLIUM)
  • TABLE 20 PIPELINE PRODUCT PROFILE (PLECANATIDE)
  • TABLE 21 GLOBAL IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
  • TABLE 22 GLOBAL PRESCRIBED DRUG MARKET BY REGION 2017-2025 ($ MILLION)
  • TABLE 23 PRODUCT PROFILE (LUBIPROSTONE)
  • TABLE 24 BRANDED IBS-C DRUGS MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 25 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
  • TABLE 26 GENERIC IBS-C DRUG MARKET BY REGION, 2017-2025 ($ MILLION)
  • TABLE 27 PRODUCT PROFILE (METAMUCIL)
  • TABLE 28 GLOBAL OVER THE COUNTER, IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  • TABLE 29 GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 30 NORTH AMERICA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
  • TABLE 31 EUROPE IBS-C DRUG MARKET 2017-2025 ($ MILLION)
  • TABLE 32 APAC IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
  • TABLE 33 ROW IBS-C DRUGS MARKET 2017-2025 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 2 GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
  • FIGURE 3 GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
  • FIGURE 4 PREVALENCE OF IBS-C IN THE GLOBAL MARKET
  • FIGURE 5 DIETS RESPONSIBLE FOR IBS
  • FIGURE 6 PERCENTAGE OF PERSONS AGED 12 AND OVER WITH DEPRESSION BY AGE AND SEX US, 2009-2012
  • FIGURE 7 DRUGS PULLED OFF FROM THE MARKET
  • FIGURE 8 LIFESTYLE AND HOME REMEDIES FOR IBS
  • FIGURE 9 US IBS-C DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 10 CANADA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 11 UK IBS-C DRUG MARKET, 2017-2025 ($ MILLION)
  • FIGURE 12 GERMANY IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
  • FIGURE 13 REST OF EUROPE IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
  • FIGURE 14 CHINA IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
  • FIGURE 15 CHINESE MEDICINE TCM TREATMENT FOR IBS
  • FIGURE 16 JAPAN IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
  • FIGURE 17 PHARMACEUTICAL MARKET SALES
  • FIGURE 18 REST OF APAC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 19 MENA IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
  • FIGURE 20 LATIN AMERICA IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
  • FIGURE 21 ROW IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
Back to Top